Volume 12, Issue 2 (Spring 2023)                   J Occup Health Epidemiol 2023, 12(2): 78-85 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hasandokht T, Maroufizadeh S, Joukar F, Salari A, Mansour-Ghanaei F. Ten-Year Cardiovascular Disease Risk Evaluation in PERSIAN Guilan Cohort Study: A Cross-Sectional Study. J Occup Health Epidemiol 2023; 12 (2) :78-85
URL: http://johe.rums.ac.ir/article-1-656-en.html

Related article in
Google Scholar

1- Associate Prof., in Preventive and Community Medicine, Cardiovascular Diseases Research Center, Dept. of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
2- Assistant Prof., in Biostatistics, Dept. of Biostatistics and Epidemiology, School of Health, Guilan University of Medical Sciences, Rasht, Iran.
3- Associate Prof., in Epidemiology, Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
4- Cardiovascular Diseases Research Center, Department of Cardiology,
5- Professor of Medicine, Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. , fmansourghanaei@gmail.com
Article history
Received: 2022/10/29
Accepted: 2023/04/16
ePublished: 2023/06/28
Subject: Epidemiology
Abstract:   (357 Views)
Background: Cardiovascular disease (CVD) is one of the most prevalent diseases worldwide including in the Asian population. CVD risk assessment provides support for policymakers for prevention strategies. This research aimed to estimate the 10-year CVD risk and evaluate the agreement between three risk scores.
Materials and Methods: A descriptive study was conducted based on 9398 subjects aged 40–70 years from 10520 PERSIAN Guilan Cohort Study (PGCS) participants in Guilan, Iran. Baseline demographic data, comorbidities, and CVD variables were derived from cohort records. The 10-year CVD risk events for every individual were calculated using three risk score models including the American College of Cardiovascular / American Heart Association (ACC/AHA) tool, Framingham Risk Score (FRS), and World Health Organization (WHO) chart. The agreement between the CVD risk scores was evaluated using the kappa statistics.
Result: The proportion of high-risk people based on WHO, FRS, and ACC/AHA was 17.5%, 16.1%, and 5.4%, respectively. WHO risk score can find the highest frequency of females with high CVD risk scores. The best agreement was observed between FRS and ACC/AHA (κw=0.672, complete agreement=82.3%). Agreement between the WHO and ACC/AHA as well as WHO and FRS was reported as κw=0.351 and κw=0.357, respectively.
Conclusions: WHO risk chart found the greatest number of people as the high-risk category. A substantial agreement was observed between FRS and ACC/AHA.


Full-Text [PDF 469 kb]   (144 Downloads)    

References
1. Tran DT, Palfrey D, Welsh R. The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease. Pharmacoecon Open. 2021;5(3):425-35. [DOI] [PMID] [PMCID]
2. Khan SS, Sidney S, Lloyd-Jones DM, Rana JS. National and Global Trends of Cardiovascular Disease Mortality, Morbidity, and Risk. In: Wong ND, Amsterdam EA, Toth PP, eds. ASPC Manual of Preventive Cardiology. Contemporary Cardiology. Berlin, Germany: Springer, Cham; 2021. PP.17-33. [DOI]
3. Malekzadeh R. Health in IranBurden of Diseases and risk factors. Tehran: Islamic Republic of Iran Ministry of Health and Medical Education, Deputy of Research and Technology; 2018 Mar.
4. Rahmani F, Asgari S, Khalili D, Habibi Moeini AS, Tohidi M, Azizi F, Hadaegh F. National trends in cardiovascular health metrics among Iranian adults using results of three cross-sectional STEPwise approaches to surveillance surveys. Sci Rep. 2021;11(1):58. [DOI] [PMID] []
5. Tran DT, Palfrey D, Welsh R. The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease. Pharmacoecon Open. 2021;5(3):425-35. [DOI] [PMID] [PMCID]
6. Siontis GC, Tzoulaki I, Siontis KC, Ioannidis JP. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ. 2012;344:e3318. [DOI] [PMID]
7. Mauricio R, Khera A. Cardiovascular Risk Assessment: From Global Risk Scoring to Risk Enhancing Factors. In: Wong, N.D., Amsterdam, E.A., Toth, P.P. eds. ASPC Manual of Preventive Cardiology. Contemporary Cardiology. Berlin, Germany: Springer, Cham; 2021. [DOI]
8. Garg N, Muduli SK, Kapoor A, Tewari S, Kumar S, Khanna R, et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline-recommended statin uses. Indian Heart J. 2017;69(4):458-63. [DOI] [PMID] [PMCID]
9. Mansour-Ghanaei F, Joukar F, Naghipour MR, Sepanlou SG, Poustchi H, Mojtahedi K, et al. The PERSIAN Guilan Cohort Study (PGCS). Arch Iran Med. 2019;22(1):39-45. [PMID]
10. Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar AA, Hekmatdoost A, et al. Prospective Epidemiological Research Studies in Iran (the PERSIAN Cohort Study): Rationale, Objectives, and Design. Am J Epidemiol. 2018;187(4):647-55. [DOI] [PMID] [PMCID]
11. Eghtesad S, Mohammadi Z, Shayanrad A, Faramarzi E, Joukar F, Hamzeh B, et al. The PERSIAN Cohort: Providing the Evidence Needed for Healthcare Reform. Arch Iran Med. 2017;20(11):691-5. [PMID]
12. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. [DOI] [PMID]
13. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935-59. [DOI] [PMID] [PMCID]
14. Mendis S, Lindholm LH, Mancia G, Whitworth J, Alderman M, Lim S, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens. 2007;25(8):1578-82. [DOI] [PMID] [PMCID]
15. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et AL. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. [DOI] [PMID]
16. Collins D, Lee J, Bobrovitz N, Koshiaris C, Ward A, Heneghan C. whoishRisk - an R package to calculate WHO/ISH cardiovascular risk scores for all epidemiological subregions of the world. F1000Res. 2016;5:2522. [DOI] [PMID] [PMCID]
17. Azadnajafabad S, Mohammadi E, Aminorroaya A, Fattahi N, Rezaei S, Haghshenas R, et al. Non-communicable diseases' risk factors in Iran; a review of the present status and action plans. J Diabetes Metab Disord. 2021:22:1-9. [DOI] [PMID] [PMCID]
18. Javanbakht M, Mashayekhi A, Baradaran HR, Haghdoost A, Afshin A. Projection of Diabetes Population Size and Associated Economic Burden through 2030 in Iran: Evidence from Micro-Simulation Markov Model and Bayesian Meta-Analysis. PLoS One. 2015;10(7):e0132505. [DOI] [PMID] [PMCID]
19. Ofori S, Dodiyi-Manuel S, Akpa MR. Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease. J Clin Lipidol. 2017;11(6):1441-7. [DOI] [PMID]
20. Alaei Faradonbeh N, Nikaeen F, Akbari M, Almasi N, Vakhshoori M. Cardiovascular disease risk prediction among Iranian patients with diabetes mellitus in Isfahan Province, Iran, in 2014, by using Framingham risk score, atherosclerotic cardiovascular disease risk score, and high-sensitive C-reactive protein. ARYA Atheroscler. 2018;14(4):163-8. [DOI] [PMID] [PMCID]
21. Mirzaei M, Mirzaei M. Agreement between Framingham, IraPEN and non-laboratory WHO-EMR risk score calculators for cardiovascular risk prediction in a large Iranian population. J Cardiovasc Thorac Res. 2020;12(1):20-6. [DOI] [PMID] [PMCID]
22. Selvarajah S, Kaur G, Haniff J, Cheong KC, Hiong TG, van der Graaf Y, et al. Comparison of the Framingham Risk Score, SCORE and WHO/ISH cardiovascular risk prediction models in an Asian population. Int J Cardiol. 2014;176(1):211-8 [DOI] [PMID]
23. Mendis S, Lindholm LH, Anderson SG, Alwan A, Koju R, Onwubere BJ, et al. Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. J Clin Epidemiol. 2011;64(12):1451-62. [DOI] [PMID]
24. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. Geneva, Switzerland: World Health Organization; 2007. [Article]
25. Chia YC, Lim HM, Ching SM. Validation of the pooled cohort risk score in an Asian population - a retrospective cohort study. BMC Cardiovasc Disord. 2014;14:163. [DOI] [PMID] []
26. Bozorgmanesh M, Hadaegh F, Azizi F. Predictive accuracy of the 'Framingham's general CVD algorithm' in a Middle Eastern population: Tehran Lipid and Glucose Study. Int J Clin Pract. 2011;65(3):264-73. [DOI] [PMID]
27. Motamed N, Mardanshahi A, Saravi BM, Siamian H, Maadi M, Zamani F. The 10-year Absolute Risk of Cardiovascular (CV) Events in Northern Iran: a Population Based Study. Mater Sociomed. 2015;27(3):158-62. [DOI] [PMID] []

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Occupational Health and Epidemiology

Designed & Developed by : Yektaweb